https://www.selleckchem.com/products/bi-2493.html
06, 2.24-7.36; p less then 0.001) was the only significant risk factor for dCCA. Statin use was associated with significantly reduced risk for all ECC (OR=0.22, 0.16-029) as well as for the subtypes pCCA (OR=0.3, 0.21-0.41) and dCCA (OR=0.06, 0.03-0.14) all p less then 0.0001. Moderate intensity dosage was found to decrease the risk of ECC (OR=0.48, 0.34-0.67, p less then 0.001). Comparing statin ever users to non-users, dCCA patients who used statins had significantly overall better survival (HR=0.53, 0.29-0.97, p=0.04). CONCLUSION Thi
Like
Comment
Share
